136 related articles for article (PubMed ID: 21777163)
1. The impact of allodynia on the efficacy of almotriptan when given early in migraine: data from the "Act when mild" study.
Díaz-Insa S; Goadsby PJ; Zanchin G; Fortea J; Falqués M; Vila C
Int J Neurosci; 2011 Dec; 121(12):655-61. PubMed ID: 21777163
[TBL] [Abstract][Full Text] [Related]
2. The 'Act when Mild' (AwM) study: a step forward in our understanding of early treatment in acute migraine.
Goadsby PJ
Cephalalgia; 2008 Sep; 28 Suppl 2():36-41. PubMed ID: 18715331
[TBL] [Abstract][Full Text] [Related]
3. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101
[TBL] [Abstract][Full Text] [Related]
4. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
5. Allodynia-associated symptoms, pain intensity and time to treatment: predicting treatment response in acute migraine intervention.
Cady RK; Freitag FG; Mathew NT; Elkind AH; Mao L; Fisher AC; Biondi DM; Finlayson G; Greenberg SJ; Hulihan JF
Headache; 2009 Mar; 49(3):350-63. PubMed ID: 19220503
[TBL] [Abstract][Full Text] [Related]
6. Early vs. non-early intervention in acute migraine-'Act when Mild (AwM)'. A double-blind, placebo-controlled trial of almotriptan.
Goadsby PJ; Zanchin G; Geraud G; de Klippel N; Diaz-Insa S; Gobel H; Cunha L; Ivanoff N; Falques M; Fortea J
Cephalalgia; 2008 Apr; 28(4):383-91. PubMed ID: 18294251
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
Diener HC
Curr Med Res Opin; 2005 Oct; 21(10):1603-10. PubMed ID: 16238900
[TBL] [Abstract][Full Text] [Related]
8. Almotriptan and its combination with aceclofenac for migraine attacks: a study of efficacy and the influence of auto-evaluated brush allodynia.
Schoenen J; De Klippel N; Giurgea S; Herroelen L; Jacquy J; Louis P; Monseu G; Vandenheede M;
Cephalalgia; 2008 Oct; 28(10):1095-105. PubMed ID: 18644036
[TBL] [Abstract][Full Text] [Related]
9. Almotriptan improves response rates when treatment is within 1 hour of migraine onset.
Dowson AJ; Massiou H; Lainez JM; Cabarrocas X
Headache; 2004 Apr; 44(4):318-22. PubMed ID: 15109355
[TBL] [Abstract][Full Text] [Related]
10. Characteristics of migraine attacks and responses to almotriptan treatment: a comparison of menstrually related and nonmenstrually related migraines.
Diamond ML; Cady RK; Mao L; Biondi DM; Finlayson G; Greenberg SJ; Wright P
Headache; 2008 Feb; 48(2):248-58. PubMed ID: 18234046
[TBL] [Abstract][Full Text] [Related]
11. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.
Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D;
Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700
[TBL] [Abstract][Full Text] [Related]
12. Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
Diener HC; Gendolla A; Gebert I; Beneke M
Headache; 2005; 45(7):874-82. PubMed ID: 15985104
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, speed of action and tolerability of almotriptan in the acute treatment of migraine: pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials.
Dahlöf CG; Pascual J; Dodick DW; Dowson AJ
Cephalalgia; 2006 Apr; 26(4):400-8. PubMed ID: 16556240
[TBL] [Abstract][Full Text] [Related]
14. Almotriptan for the treatment of acute migraine: a review of early intervention trials.
Antonaci F; De Cillis I; Cuzzoni MG; Allena M
Expert Rev Neurother; 2010 Mar; 10(3):351-64. PubMed ID: 20187858
[TBL] [Abstract][Full Text] [Related]
15. Defeating migraine pain with triptans: a race against the development of cutaneous allodynia.
Burstein R; Collins B; Jakubowski M
Ann Neurol; 2004 Jan; 55(1):19-26. PubMed ID: 14705108
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of early versus non-early intervention in acute migraine based on evidence from the 'Act when Mild' study.
Slof J
Appl Health Econ Health Policy; 2012 May; 10(3):201-15. PubMed ID: 22320449
[TBL] [Abstract][Full Text] [Related]
17. Almotriptan and zolmitriptan in the acute treatment of migraine.
Goadsby PJ; Massiou H; Pascual J; Diener HC; Dahlöf CG; Mateos V; Dowson AJ; Raets I; Cunha L; Färkkilä M; Manzoni GC
Acta Neurol Scand; 2007 Jan; 115(1):34-40. PubMed ID: 17156263
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of almotriptan versus zolmitriptan for the acute treatment of menstrual migraine.
Allais G; Acuto G; Cabarrocas X; Esbri R; Benedetto C; Bussone G
Neurol Sci; 2006 May; 27 Suppl 2():S193-7. PubMed ID: 16688629
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and tolerability of almotriptan in controlled clinical trials.
Mathew NT
Eur Neurol; 2005; 53 Suppl 1():29-33. PubMed ID: 15920335
[TBL] [Abstract][Full Text] [Related]
20. Clarification of developing and established clinical allodynia and pain-free outcomes.
Landy SH; McGinnis JE; McDonald SA
Headache; 2007 Feb; 47(2):247-52. PubMed ID: 17300364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
